Immuneering (NASDAQ:IMRX) Lowered to “Sell” Rating by Wall Street Zen

Immuneering (NASDAQ:IMRX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on IMRX. Oppenheimer restated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Immuneering in a report on Tuesday, May 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Immuneering in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Stock Up 1.7%

Shares of NASDAQ IMRX opened at $4.19 on Friday. The business’s 50 day moving average price is $5.17 and its two-hundred day moving average price is $5.43. The company has a market cap of $271.09 million, a PE ratio of -3.58 and a beta of 0.38. Immuneering has a twelve month low of $1.66 and a twelve month high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. As a group, research analysts anticipate that Immuneering will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Immuneering

A number of large investors have recently modified their holdings of IMRX. Empery Asset Management LP acquired a new stake in shares of Immuneering in the 4th quarter valued at $17,601,000. State Street Corp lifted its stake in shares of Immuneering by 1,289.7% in the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock valued at $15,807,000 after acquiring an additional 2,229,374 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Immuneering during the 3rd quarter valued at $6,602,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of Immuneering during the 3rd quarter valued at $3,850,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.